Hearts From Donors Who Had COVID Are Safe for Transplant
MONDAY, Oct. 31, 2022 -- A person with heart failure in dire need of a new heart may have faced delays in getting one during the pandemic when potential donors tested positive for COVID-19.
As some centers began accepting these hearts for transplant... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 31, 2022 Category: General Medicine Source Type: news
How 7 People With Diabetes Manage Their Blood Sugar
If only there existed a simple set of rules for managing blood sugar when you have Type 2 diabetes—it would be the most-requested pamphlet in a doctor’s office. Instead, as many people find, there’s no one-size-fits-all solution for the millions of Americans with the condition. It takes time and effort to discover what works best, and the right combination will differ for everyone.
Determining what type of medication and which lifestyle factors will be most effective for managing blood sugar could take years. One way to speed up the discovery? Learn from others who are living with the condition. Here, sev...
Source: TIME: Health - October 28, 2022 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized Disease healthscienceclimate Source Type: news
VADs, Transplant Used Less in Black Patients With Heart Failure
WEDNESDAY, Oct. 26, 2022 -- Among heart failure patients with high-risk features, there is less utilization of ventricular assist devices (VADs) and transplant among Black patients, with no increase in mortality, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 26, 2022 Category: Pharmaceuticals Source Type: news
Ethical Quandaries With Pig-Heart Transplants at the Crossroads Ethical Quandaries With Pig-Heart Transplants at the Crossroads
Tough questions need asking. Should xenotransplant research have its own rules? Should society be wary of the unique risks? Should patients bear extra responsibilities and give up some rights?Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 25, 2022 Category: Cardiology Tags: Cardiology News Source Type: news
U.S. FDA Approves TECVAYLI ™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., October 25, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) approved TECVAYLI™ (teclistamab-cqyv) for the treatment of adult patients with relapsed or refractory multiple myeloma, who previously received four or more prior lines of therapy, including a proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.1 TECVAYLI™ is a first-in-class, bispecific T-cell engager antibody that is administered as a subcutaneous treatment.1 This off-the-shelf (or ready to use) therapy uses innovative science to ac...
Source: Johnson and Johnson - October 25, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
